首页 > 最新文献

European Journal of Human Genetics最新文献

英文 中文
Enhancing the detection of familial hypercholesterolaemia in general practice: A model for supporting genetic cascade testing in the community 在一般实践中加强家族性高胆固醇血症的检测:支持社区基因级联检测的模型。
IF 4.6 2区 生物学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2025-11-17 DOI: 10.1038/s41431-025-01979-7
Jing Pang, Wendy Barnett, Jane Purdie, Jennifer A. Della-Vedova, Annmarie Woodward, Damon A. Bell, Amanda J. Hooper, Dick C. Chan, Andrew C. Martin, Kristen J. Nowak, Jacquie Garton-Smith, Gerald F. Watts
Familial hypercholesterolaemia (FH) is a common, co-dominant cause of premature coronary artery disease that remains under-recognised worldwide. Genetic testing, the most accurate diagnostic method, is particularly valuable in the cascade testing of close blood relatives, but there is little experience in general practice. We developed a tertiary-primary shared care model to identify genetic FH among first-degree relatives (FDRs) of FH index cases. Service and clinical outcomes were assessed. From a total of 153 FDRs of 90 adult FH index cases, 105 (corresponding to 64 index cases) undertook genetic testing by their general practitioner (GP). Median age of the FDRs was 14.8 years (range 3–79 years), 54% being male, 80% Caucasian, 61% children/adolescents, and 80% progeny. The number of new FDRs with a pathogenic variant per index case was 0.89 (95% CI, 0.69–1.10), with an uptake and yield of testing of 95% and 50%, respectively. Relatives with a pathogenic variant had significantly higher LDL-cholesterol than those without (5.9 ± 1.8 vs. 2.7 ± 0.9 mmol/L, p < 0.001). Among 31 relatives initiated on treatment after a genetic diagnosis, a 46% reduction in LDL-cholesterol was achieved with 45% attaining guideline-directed goals. Genetic cascade testing of FDRs of index cases with FH is feasible and effective in a shared-care model in which GPs are supported by a tertiary centre. These preliminary findings inform the development of centralised and sustained models of care, with implications for the detection of FH in communities.
家族性高胆固醇血症(FH)是一种常见的、共同主导的过早冠状动脉疾病的原因,在世界范围内仍未得到充分认识。基因检测是最准确的诊断方法,在近亲的级联检测中特别有价值,但在一般实践中缺乏经验。我们开发了一个三级-初级共同护理模型,以确定FH指数病例的一级亲属(fdr)的遗传性FH。评估服务和临床结果。在90名成人FH指数病例的153名fdr中,105名(相当于64名指数病例)接受了全科医生的基因检测。fdr的中位年龄为14.8岁(范围3-79岁),54%为男性,80%为白种人,61%为儿童/青少年,80%为后代。每个指数病例中带有致病变异的新fdr数为0.89 (95% CI, 0.69-1.10),检测的吸收率和产率分别为95%和50%。有致病变异的亲属ldl -胆固醇明显高于无致病变异的亲属(5.9±1.8 vs. 2.7±0.9 mmol/L, p
{"title":"Enhancing the detection of familial hypercholesterolaemia in general practice: A model for supporting genetic cascade testing in the community","authors":"Jing Pang,&nbsp;Wendy Barnett,&nbsp;Jane Purdie,&nbsp;Jennifer A. Della-Vedova,&nbsp;Annmarie Woodward,&nbsp;Damon A. Bell,&nbsp;Amanda J. Hooper,&nbsp;Dick C. Chan,&nbsp;Andrew C. Martin,&nbsp;Kristen J. Nowak,&nbsp;Jacquie Garton-Smith,&nbsp;Gerald F. Watts","doi":"10.1038/s41431-025-01979-7","DOIUrl":"10.1038/s41431-025-01979-7","url":null,"abstract":"Familial hypercholesterolaemia (FH) is a common, co-dominant cause of premature coronary artery disease that remains under-recognised worldwide. Genetic testing, the most accurate diagnostic method, is particularly valuable in the cascade testing of close blood relatives, but there is little experience in general practice. We developed a tertiary-primary shared care model to identify genetic FH among first-degree relatives (FDRs) of FH index cases. Service and clinical outcomes were assessed. From a total of 153 FDRs of 90 adult FH index cases, 105 (corresponding to 64 index cases) undertook genetic testing by their general practitioner (GP). Median age of the FDRs was 14.8 years (range 3–79 years), 54% being male, 80% Caucasian, 61% children/adolescents, and 80% progeny. The number of new FDRs with a pathogenic variant per index case was 0.89 (95% CI, 0.69–1.10), with an uptake and yield of testing of 95% and 50%, respectively. Relatives with a pathogenic variant had significantly higher LDL-cholesterol than those without (5.9 ± 1.8 vs. 2.7 ± 0.9 mmol/L, p &lt; 0.001). Among 31 relatives initiated on treatment after a genetic diagnosis, a 46% reduction in LDL-cholesterol was achieved with 45% attaining guideline-directed goals. Genetic cascade testing of FDRs of index cases with FH is feasible and effective in a shared-care model in which GPs are supported by a tertiary centre. These preliminary findings inform the development of centralised and sustained models of care, with implications for the detection of FH in communities.","PeriodicalId":12016,"journal":{"name":"European Journal of Human Genetics","volume":"34 2","pages":"252-259"},"PeriodicalIF":4.6,"publicationDate":"2025-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145539801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Brugada Syndrome: an exemplar for the genomic basis of sudden death. Brugada综合征:猝死基因组基础的一个范例。
IF 4.6 2区 生物学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2025-11-14 DOI: 10.1038/s41431-025-01972-0
Rebecca L M Griffiths, Roddy Walsh, Marta Futema, Mark Specterman, Elijah R Behr

The inherited arrhythmia syndrome, Brugada Syndrome (BrS), is a leading cause of autopsy negative sudden death: the sudden arrhythmic death syndrome. Historically, BrS was believed to exhibit a Mendelian (autosomal dominant) mode of inheritance, caused by rare variants in SCN5A, the gene coding for the alpha subunit of the main cardiac sodium voltage channel. Challenges to this paradigm have arisen. For example, the majority of BrS cases do not exhibit rare variants in SCN5A. Moreover, genotype-phenotype mismatch in families has been observed. These findings suggest a more complex genetic architecture underpinning BrS. Subsequent large genomic studies of international patient cohorts have shown an unexpectedly high contribution of common genetic variation to its phenotypic development and severity. This has led to an alternative disease hypothesis whereby BrS develops as result of accumulated genetic and environmental risk surpassing a 'disease threshold' - the higher the accumulated risk, the more severe the clinical phenotype. Whilst expansion of standard clinical genetic testing to include an assessment of common variation might assist with diagnosis and phenotypic severity prediction in BrS, its incorporation into clinical practice presents inherent challenges which require careful consideration.

遗传性心律失常综合征,Brugada综合征(BrS),是尸检阴性猝死的主要原因:突发性心律失常死亡综合征。从历史上看,BrS被认为表现出孟德尔(常染色体显性)遗传模式,由SCN5A的罕见变异引起,SCN5A是编码心脏钠主电压通道α亚基的基因。对这一范式的挑战已经出现。例如,大多数BrS病例在SCN5A中不表现出罕见的变异。此外,还观察到家族中基因型-表型不匹配。这些发现表明,支持BrS的遗传结构更为复杂。随后对国际患者队列进行的大型基因组研究显示,共同遗传变异对其表型发展和严重程度的贡献出乎意料地高。这导致了另一种疾病假说,即BrS的发展是累积的遗传和环境风险超过“疾病阈值”的结果——累积的风险越高,临床表型就越严重。虽然将标准临床基因检测扩展到包括对常见变异的评估可能有助于BrS的诊断和表型严重程度预测,但将其纳入临床实践存在固有的挑战,需要仔细考虑。
{"title":"Brugada Syndrome: an exemplar for the genomic basis of sudden death.","authors":"Rebecca L M Griffiths, Roddy Walsh, Marta Futema, Mark Specterman, Elijah R Behr","doi":"10.1038/s41431-025-01972-0","DOIUrl":"https://doi.org/10.1038/s41431-025-01972-0","url":null,"abstract":"<p><p>The inherited arrhythmia syndrome, Brugada Syndrome (BrS), is a leading cause of autopsy negative sudden death: the sudden arrhythmic death syndrome. Historically, BrS was believed to exhibit a Mendelian (autosomal dominant) mode of inheritance, caused by rare variants in SCN5A, the gene coding for the alpha subunit of the main cardiac sodium voltage channel. Challenges to this paradigm have arisen. For example, the majority of BrS cases do not exhibit rare variants in SCN5A. Moreover, genotype-phenotype mismatch in families has been observed. These findings suggest a more complex genetic architecture underpinning BrS. Subsequent large genomic studies of international patient cohorts have shown an unexpectedly high contribution of common genetic variation to its phenotypic development and severity. This has led to an alternative disease hypothesis whereby BrS develops as result of accumulated genetic and environmental risk surpassing a 'disease threshold' - the higher the accumulated risk, the more severe the clinical phenotype. Whilst expansion of standard clinical genetic testing to include an assessment of common variation might assist with diagnosis and phenotypic severity prediction in BrS, its incorporation into clinical practice presents inherent challenges which require careful consideration.</p>","PeriodicalId":12016,"journal":{"name":"European Journal of Human Genetics","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145523281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The efficacy of genetic counselling for familial colorectal cancer. A randomised clinical trial 家族性结直肠癌遗传咨询的疗效分析。一项随机临床试验。
IF 4.6 2区 生物学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2025-11-07 DOI: 10.1038/s41431-025-01921-x
Andrada Ciucă, Tara Clancy, Sebastian Pintea, Ramona Moldovan
Genetic counselling (GC) for familial colorectal cancer (fCRC) has been previously shown to improve outcomes such as emotional distress and screening adherence. This is the first randomised clinical trial to evaluate the efficacy of GC for fCRC. We included individuals affected or at-risk for fCRC (Lynch syndrome, APC-associated polyposis, other risk-associated pathogenic variants and clinically defined fCRC). Participants were randomised to (1) standard care or (2) standard care and genetic counselling. Measures include empowerment, anxiety, depression, knowledge, emotional distress, perceived social support, risk perception. Eighty-two individuals participated in the study. The average age was 44.81 years old, with 52.4% women. There was a significant effect in the counselling group (42/82) on post-intervention empowerment scores compared to the control group (40/82) (p = 0.004, d = 0.71), and similarly for depression (p = 0.025, d = 0.40), anxiety (p = 0.036, d = 0.35) and knowledge (p = 0.016, d = 0.25). Exploratory analysis show that several sociodemographic, affective and cognitive variables are moderating the improvement in empowerment following genetic counselling. Our data show significant improvements for both primary endpoint (empowerment) and secondary endpoints (knowledge, depression, anxiety, emotional distress). Genetic counselling is an effective intervention for fCRC both when the diagnosis is part of a syndrome or clinically defined, and both for affected or at-risk individuals.
家族性结直肠癌(fCRC)的遗传咨询(GC)先前已被证明可以改善情绪困扰和筛查依从性等结果。这是首个评估GC治疗fCRC疗效的随机临床试验。我们纳入了受fCRC影响或有fCRC风险的个体(Lynch综合征、apc相关息肉病、其他风险相关致病变异和临床定义的fCRC)。参与者被随机分配到(1)标准治疗组或(2)标准治疗和遗传咨询组。衡量标准包括赋权、焦虑、抑郁、知识、情绪困扰、感知社会支持、风险感知。82个人参与了这项研究。平均年龄44.81岁,女性占52.4%。辅导组(42/82)干预后赋权得分与对照组(40/82)比较差异有统计学意义(p = 0.004, d = 0.71),抑郁(p = 0.025, d = 0.40)、焦虑(p = 0.036, d = 0.35)、知识(p = 0.016, d = 0.25)得分差异有统计学意义(p = 0.036, d = 0.35)。探索性分析表明,一些社会人口、情感和认知变量正在调节遗传咨询后赋权的改善。我们的数据显示,主要终点(赋权)和次要终点(知识、抑郁、焦虑、情绪困扰)均有显著改善。遗传咨询对于fCRC是一种有效的干预手段,无论是当诊断为综合征的一部分或临床定义时,还是对于受影响或有风险的个体。
{"title":"The efficacy of genetic counselling for familial colorectal cancer. A randomised clinical trial","authors":"Andrada Ciucă,&nbsp;Tara Clancy,&nbsp;Sebastian Pintea,&nbsp;Ramona Moldovan","doi":"10.1038/s41431-025-01921-x","DOIUrl":"10.1038/s41431-025-01921-x","url":null,"abstract":"Genetic counselling (GC) for familial colorectal cancer (fCRC) has been previously shown to improve outcomes such as emotional distress and screening adherence. This is the first randomised clinical trial to evaluate the efficacy of GC for fCRC. We included individuals affected or at-risk for fCRC (Lynch syndrome, APC-associated polyposis, other risk-associated pathogenic variants and clinically defined fCRC). Participants were randomised to (1) standard care or (2) standard care and genetic counselling. Measures include empowerment, anxiety, depression, knowledge, emotional distress, perceived social support, risk perception. Eighty-two individuals participated in the study. The average age was 44.81 years old, with 52.4% women. There was a significant effect in the counselling group (42/82) on post-intervention empowerment scores compared to the control group (40/82) (p = 0.004, d = 0.71), and similarly for depression (p = 0.025, d = 0.40), anxiety (p = 0.036, d = 0.35) and knowledge (p = 0.016, d = 0.25). Exploratory analysis show that several sociodemographic, affective and cognitive variables are moderating the improvement in empowerment following genetic counselling. Our data show significant improvements for both primary endpoint (empowerment) and secondary endpoints (knowledge, depression, anxiety, emotional distress). Genetic counselling is an effective intervention for fCRC both when the diagnosis is part of a syndrome or clinically defined, and both for affected or at-risk individuals.","PeriodicalId":12016,"journal":{"name":"European Journal of Human Genetics","volume":"34 1","pages":"70-77"},"PeriodicalIF":4.6,"publicationDate":"2025-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41431-025-01921-x.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145470876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advancing towards clear and patient-centred language in cancer genetics. 癌症遗传学向着清晰和以患者为中心的语言迈进。
IF 4.6 2区 生物学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2025-11-05 DOI: 10.1038/s41431-025-01976-w
Saar Van Pottelberghe, Frederik J Hes, Maurizio Genuardi

Language in clinical genetics is never neutral. The terms used to describe genetic concepts, like mutation or variant, sporadic or hereditary, patient or counselee not only shape scientific discourse but also profoundly affect how individuals understand their risks, experience counselling, and make decisions. Terminology carries ethical weight, influencing perceptions of identity, stigma, and inclusion. Precision and empathy in language are therefore central to ethical and effective care. We propose the use of consistent terminology in communication that integrates three ethical responsibilities, promoting inclusivity through careful terminology, fostering psychosocial awareness by recognising that words can evoke fear or stigma, or offer reassurance and communicative clarity. This can be achieved by standardising professional terminology (e.g., variant, sporadic/hereditary) while co-constructing meaning with counselees. We recommend avoiding ambiguous labels like positive or negative, using precise qualifiers for variants and harmonising language across professional disciplines. Communication itself can be a clinical intervention, as careful paraphrasing and clarification both enhance understanding and provide emotional support. As genetic testing becomes increasingly mainstream in oncology, empathetic, precise, and patient-centred communication is essential. By fostering clarity and reducing stigma, language can support informed decision-making, trust, and ultimately, the ethical integration of genetics into everyday healthcare.

临床遗传学的语言从来不是中立的。用于描述基因概念的术语,如突变或变异,零星或遗传,患者或咨询者,不仅塑造了科学话语,而且深刻影响了个人如何理解他们的风险,经历咨询和做出决定。术语具有伦理意义,影响身份、污名和包容的观念。因此,语言的精确性和同理心是道德和有效护理的核心。我们建议在沟通中使用统一的术语,整合三种道德责任,通过谨慎的术语促进包容性,通过认识到词语可能引起恐惧或耻辱来培养社会心理意识,或提供安慰和沟通清晰度。这可以通过标准化专业术语(例如,变体,零星/遗传)来实现,同时与咨询师共同构建意义。我们建议避免模棱两可的标签,如肯定或否定,使用精确的限定词的变体和协调跨专业学科的语言。沟通本身可以是一种临床干预,因为仔细的解释和澄清既能增进理解,又能提供情感支持。随着基因检测在肿瘤学领域日益成为主流,同理心、精确和以患者为中心的沟通是必不可少的。通过提高清晰度和减少耻辱感,语言可以支持明智的决策、信任,并最终将遗传学纳入日常医疗保健。
{"title":"Advancing towards clear and patient-centred language in cancer genetics.","authors":"Saar Van Pottelberghe, Frederik J Hes, Maurizio Genuardi","doi":"10.1038/s41431-025-01976-w","DOIUrl":"https://doi.org/10.1038/s41431-025-01976-w","url":null,"abstract":"<p><p>Language in clinical genetics is never neutral. The terms used to describe genetic concepts, like mutation or variant, sporadic or hereditary, patient or counselee not only shape scientific discourse but also profoundly affect how individuals understand their risks, experience counselling, and make decisions. Terminology carries ethical weight, influencing perceptions of identity, stigma, and inclusion. Precision and empathy in language are therefore central to ethical and effective care. We propose the use of consistent terminology in communication that integrates three ethical responsibilities, promoting inclusivity through careful terminology, fostering psychosocial awareness by recognising that words can evoke fear or stigma, or offer reassurance and communicative clarity. This can be achieved by standardising professional terminology (e.g., variant, sporadic/hereditary) while co-constructing meaning with counselees. We recommend avoiding ambiguous labels like positive or negative, using precise qualifiers for variants and harmonising language across professional disciplines. Communication itself can be a clinical intervention, as careful paraphrasing and clarification both enhance understanding and provide emotional support. As genetic testing becomes increasingly mainstream in oncology, empathetic, precise, and patient-centred communication is essential. By fostering clarity and reducing stigma, language can support informed decision-making, trust, and ultimately, the ethical integration of genetics into everyday healthcare.</p>","PeriodicalId":12016,"journal":{"name":"European Journal of Human Genetics","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145451344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Commentary on the LMSz method: a novel approach to gene-specific growth charts for rare neurodevelopmental disorders. LMSz方法:罕见神经发育障碍基因特异性生长图的新方法。
IF 4.6 2区 生物学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2025-11-03 DOI: 10.1038/s41431-025-01975-x
Gyaneshwer Chaubey
{"title":"Commentary on the LMSz method: a novel approach to gene-specific growth charts for rare neurodevelopmental disorders.","authors":"Gyaneshwer Chaubey","doi":"10.1038/s41431-025-01975-x","DOIUrl":"10.1038/s41431-025-01975-x","url":null,"abstract":"","PeriodicalId":12016,"journal":{"name":"European Journal of Human Genetics","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145437868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Insights in genetics: from molecular mechanisms to patient perspectives 遗传学的见解:从分子机制到患者的观点
IF 4.6 2区 生物学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2025-11-03 DOI: 10.1038/s41431-025-01970-2
Seda S. Zonuzi
{"title":"Insights in genetics: from molecular mechanisms to patient perspectives","authors":"Seda S. Zonuzi","doi":"10.1038/s41431-025-01970-2","DOIUrl":"10.1038/s41431-025-01970-2","url":null,"abstract":"","PeriodicalId":12016,"journal":{"name":"European Journal of Human Genetics","volume":"33 11","pages":"1387-1388"},"PeriodicalIF":4.6,"publicationDate":"2025-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41431-025-01970-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145426310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstracts from the 58th European Society of Human Genetics (ESHG) Conference: ePosters. 第58届欧洲人类遗传学学会(ESHG)会议摘要:电子海报。
IF 4.6 2区 生物学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2025-11-01 DOI: 10.1038/s41431-025-01934-6
{"title":"Abstracts from the 58<sup>th</sup> European Society of Human Genetics (ESHG) Conference: ePosters.","authors":"","doi":"10.1038/s41431-025-01934-6","DOIUrl":"10.1038/s41431-025-01934-6","url":null,"abstract":"","PeriodicalId":12016,"journal":{"name":"European Journal of Human Genetics","volume":"33 Suppl 1","pages":"110-507"},"PeriodicalIF":4.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12588389/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145444461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstracts from the 58th European Society of Human Genetics (ESHG) Conference: Hybrid Posters. 第58届欧洲人类遗传学学会(ESHG)会议:杂交海报摘要。
IF 4.6 2区 生物学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2025-11-01 DOI: 10.1038/s41431-025-01935-5
{"title":"Abstracts from the 58<sup>th</sup> European Society of Human Genetics (ESHG) Conference: Hybrid Posters.","authors":"","doi":"10.1038/s41431-025-01935-5","DOIUrl":"10.1038/s41431-025-01935-5","url":null,"abstract":"","PeriodicalId":12016,"journal":{"name":"European Journal of Human Genetics","volume":"33 Suppl 1","pages":"508-1220"},"PeriodicalIF":4.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12588390/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145444379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstracts from the 58th European Society of Human Genetics (ESHG) Conference. 第58届欧洲人类遗传学学会(ESHG)会议摘要
IF 4.6 2区 生物学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2025-11-01 DOI: 10.1038/s41431-025-01936-4
{"title":"Abstracts from the 58<sup>th</sup> European Society of Human Genetics (ESHG) Conference.","authors":"","doi":"10.1038/s41431-025-01936-4","DOIUrl":"10.1038/s41431-025-01936-4","url":null,"abstract":"","PeriodicalId":12016,"journal":{"name":"European Journal of Human Genetics","volume":"33 Suppl 1","pages":"3-109"},"PeriodicalIF":4.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12588387/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145444406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstracts from the 58th European Society of Human Genetics (ESHG) Conference. 第58届欧洲人类遗传学学会(ESHG)会议摘要
IF 4.6 2区 生物学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2025-11-01 DOI: 10.1038/s41431-025-01932-8
{"title":"Abstracts from the 58<sup>th</sup> European Society of Human Genetics (ESHG) Conference.","authors":"","doi":"10.1038/s41431-025-01932-8","DOIUrl":"10.1038/s41431-025-01932-8","url":null,"abstract":"","PeriodicalId":12016,"journal":{"name":"European Journal of Human Genetics","volume":"33 Suppl 1","pages":"1-2"},"PeriodicalIF":4.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711160/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145444393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European Journal of Human Genetics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1